Clinical Trials Browser

Phase 1 × Prostatic Neoplasms × Temozolomide × Clear all

NCT01085422 2017-11-21

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms